科伦药业：子公司产品芦康沙妥珠单抗(sac-TMT)获批第二个适应症

Core Viewpoint - Kelong Pharmaceutical's subsidiary, Sichuan Kelong Botai Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for its antibody-drug conjugate (ADC) sac-TMT, marking it as the first TROP2 ADC drug approved for lung cancer indications globally [1] Company Summary - Kelong Pharmaceutical's ADC sac-TMT is now approved for a second indication, specifically for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy [1] - The approval signifies a significant advancement in treatment options, as sac-TMT has shown to significantly extend overall survival benefits compared to current standard treatments for this patient population [1]